Determinants of control of high blood pressure. The Oslo Health Study 2000-2001

Blood Pressure

Volumn 13, Issue 6, 2004, Pages 343-349

  Tonstad, Serena ^a   Furu, Kari ^b,c   Rosvold, Elin Olaug ^b   Skurtveit, Svetlana ^c  

^a ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Antihypertensive treatment; Blood pressure control; Cardiovascular disease; Diabetes; Population based survey

Indexed keywords

ACETYLSALICYLIC ACID; ANTIHYPERTENSIVE AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT;

ADULT; AGE; AGED; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CIGARETTE SMOKING; COMORBIDITY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DRUG USE; FEMALE; HEALTH SURVEY; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; NORWAY; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; SEX DIFFERENCE; SYSTOLIC BLOOD PRESSURE;

EID: 11144323735     PISSN: 08037051     EISSN: None     Source Type: Journal    
DOI: 10.1080/08037050410003982     Document Type: Article

References (38)

1. Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. JAMA 2003; 289: 2363-9.
2. Guidelines Committee. 2003 European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003; 21: 1011-53.
3. Chobanian A, Bakris GL, Black HR, et al. The seventh report of the Joint National committee on prevention, detection, evaluation, and treatment of high blood pressure. The JNC7 report. JAMA 2003; 289: 2560-72.
4. Wolf-Maier K, Cooper RS, Kramer H, et al. Hypertension treatment and control in five European countries, Canada, and the United States. Hypertension 2004; 43: 10-17.
5. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries. Principal results from EUROASPIRE II Euro Heart Survey program. Eur Heart J 2001; 22: 554-72.
6. Berlowitz DR, Ash AS, Hickey EC, et al. Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998; 339: 1957-63.
7. O'Connor PJ. Overcome clinical inertia to control systolic blood pressure. Arch Intern Med 2003; 263: 2677-8.
8. Hetlevik I, Holmen J, Krüger Ø, Holen A. Fifteen years with clinical guidelines in the treatment of hypertension - still discrepancies between intentions and practice. Scand J Primary Health Care 1997; 15: 134-40.
9. Oliveria SA, Lapuerta P, McCarthy BD, LåItalien GJ, Berlowitz DR, Asch SM. Physician-related barriers to the effective management of uncontrolled hypertension. Arch Intern Med 2002; 162: 413-20.
10. Waeber B. Treatment strategy to control blood pressure optimally in hypertensive patients. Blood Press 2001; 10: 62-73.
11. Waeber B, Brunner HR. The multifactorial nature of hypertension: the greatest challenge for its treatment? J Hypertens 2001; 19 Suppl 3: S9-16.
12. Per G. Lund-Larsen: Arven fra Statens skjermbildefotografering (SSF)/Statens helseundersøkelser (SHUS): En introduksjon til databanken. Nor J Epidemiol 2003; 13: 4-18. Full text available: http://www.medisin.ntnu.no/ism/nofe/norepid/2003(1)%2004-Innledning.pdf.
13. Vollset SE. Confidence intervals for a binomial proportion. Stat Med 1993; 12: 808-24.
14. Borzecki AM, Wong AT, Hickey EC, Ash AS, Berlowitz DR. Hypertension control. How well are we doing? Arch Intern Med 2003; 163: 2705-11.
15. Berlowitz DR, Ash AS, Hickey EC, et al. Hypertension management in diabetes: the need for more aggressive therapy. Diabetes Care 2003; 26: 355-9.
16. Tonstad S, Rosvold EO, Furu K, Skurtveit S. Undertreatment and overtreatment with statins: the Oslo Health Study 2000-2001. J Intern Med 2004; 255: 494-502.
17. Kanbay M, Yildirir A, Bozbas H, Ulus T, Demirtas K, Muderrisoglu H. Atorvastatin therapy helps to control blood pressure levels in hypertensive dyslipidemic patients. Atherosclerosis 2004; 5 Suppl 1: 126.
18. Schelleman H, Klungel OH, Kromhout D, de Boer A, Stricker BH, Verschuren W. Prevalence and determinants of undertreatment of hypertension in the Netherlands. J Human Hypertens 2004; 18: 317-24.
19. Hyman DJ, Pavlik VN. Characteristics of patients with uncontrolled hypertension in the United States. N Engl J Med 2001; 345: 479-86.
20. Barker WH, Mullooly JP, Linton KL. Trends in hypertension prevalence, treatment, and control in a well-defined older population. Hypertension 1998; 31: 552-9.
21. Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. JAMA 2003; 290: 199-206.
22. De Backer G, Ambrosioni E, Borch-Johnsen K, et al. Third joint task force of European and other societies on Cardiovascular Disease Prevention in Clinical Practice. European guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J 2003; 24: 1601-10.
23. Omvik P. How smoking affects blood pressure. Blood Press 1996; 5: 71-7.
24. Lee DH, Ha MH, Kim JR, et al. Effects of smoking cessation on changes in blood pressure and incidence of hypertension: a 4-year follow-up study. Hypertension 2001; 37: 194-8.
25. Green MS, Harari G. A prospective study of effects of changes in smoking habits on blood counts, serum lipids and lipoproteins, body weight and blood pressure in occupationally active men. The Israeli Cordi study. J Cli Epidemiol 1995; 9: 1159-66.
26. Janzon E, Hedblad B, Berglund G, Engström G. Changes in blood pressure and body weight following smoking cessation in women. J Intern Med 2004; 255: 266-72.
27. Primatesta P, Falschetti E, Gupta S, Marmot MG, Poulter NR. Association between smoking and blood pressure. Evidence from the Health Survey for England. Hypertension 2001; 37: 187-93.
28. US Department of Health and Human Services. Healthy People 2010: Understanding and improving health, 2nd edition. Washington, DC: US Government Printing Office, 2000: 12-22.
29. Holmen J, editor Høyt blodtrykk. NSAMs handlingsprogram. Utredningsrapport nr. U3-1993. Seksjon for helsetjenesteforskning. Samfunnsmedisinsk forskningssenter. Verdal: Statens Institutt for Folkehelse, 1993.
30. Meland E, Ellekjær H, Gjelsvik B, Kimsås A, Holmen J, Hetlevik I. Pharmacological prevention of cardiovascular disease in general practice. Tidsskr Nor Lægeforen 2000; 120: 2643-7.
31. Petersen H, Næss A-C, Dalsegg A, et al Behandling av mild hypertensjon. Konsensuskonferanse. Oslo: Norges forskningsråd. Komiteen for medisinsk teknologivurdering, 1997.
32. Hetlevik I, Holmen J, Krüger Ø, Kristensen P, Iversen H. Implementing clinical guidelines in the treatment of hypertension in general practice. Blood Press 1998; 7: 1-7.
33. MacMahon S, Peto R, Cutler J, et al. Blood pressure, stroke and coronary heart disease part I. Prolonged differences in blood pressure: prospective observational studies corrected for regression dilution bias. Lancet 1990; 335: 765-74.
34. Birkett NJ, Donner AP, Maynard MD. Assessing hypertension control in the community: the need for follow-up measurements to ensure clinical relevance. Can Med Assoc J 1987; 136: 595-600.
35. Furu K, Skurtveit S, Rosvold EO. Drug use questions in Norwegian health surveys - response rate and agreement between specific and open-ended questions. Nor J Epidemiol 2003; 13: 147-54.
36. Enlund H, Tuomilehto J, Turakka H. Patient report validated against prescription records for measuring use of and compliance with antihypertensive drugs. Acta Med Scand 1981; 209: 271-5.
37. Klungel OH, de Boer A, Paes AHP, Herings RMC, Seidell JC, Bakker A. Agreement between self-reported antihypertensive drug use and pharmacy records in a population-based study in The Netherlands. Pharmacy World & Science 1999; 21: 217-20.
38. Søgaard AJ, Selmer R, Bjertness E, Thelle D. The Oslo Health Study. The impact of self-selection in a large, population-based survey. Int J Equity Health 2004; 3: 3Online: http://www.equityhealthj.com/content/3/1/3.